Deerfield Management Company, L.P. (Series C) Avadel Pharmaceuticals PLC Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$3.34 - $7.7 $9.09 Million - $21 Million	-2,722,241 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$5.89 - $7.78 $6.28 Million - $8.3 Million	-1,066,299 Reduced 28.15%	2,722,241 $16.7 Million
Q1 2018 May 15, 2018	SELL	$6.76 - $11.7 $1.13 Million - $1.95 Million	-166,954 Reduced 4.22%	3,788,540 $27.6 Million
Q4 2017 Feb 14, 2018	BUY	$8.03 - $11.25 $2.41 Million - $3.38 Million	300,000 Added 8.21%	3,955,494 $32.4 Million
Q3 2017 Nov 13, 2017	BUY	$8.35 - $10.5 $30.5 Million - $38.4 Million	3,655,494	3,655,494 $38.4 Million

Others Institutions Holding AVDL

# of Institutions

Shares Held

1.07M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account